Target Name: ATP6V1H
NCBI ID: G51606
Review Report on ATP6V1H Target / Biomarker Content of Review Report on ATP6V1H Target / Biomarker
ATP6V1H
Other Name(s): V-ATPase H subunit | VATH_HUMAN | V-ATPase subunit H | SFDalpha | NBP1 | Vacuolar proton pump H subunit | vacuolar proton pump subunit H | ATPase H+ transporting V1 subunit H | vacuolar ATP synthase subunit H | Vacuolar proton pump subunit H | Protein VMA13 homolog | ATPase H+ transporting V1 subunit H, transcript variant 1 | SFDbeta | SFD | protein VMA13 homolog | V-ATPase 50/57 kDa subunits | V-type proton ATPase subunit H (isoform 1) | vacuolar ATPase subunit H | ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H | Vacuolar ATPase subunit H | Vacuolar ATP synthase subunit H | MSTP042 | CGI-11 | VMA13 | Nef-binding protein 1 | ATP6V1H variant 1 | Vacuolar proton pump subunit SFD | vacuolar proton pump subunit SFD | V-type proton ATPase subunit H | nef-binding protein 1

Unlocking the Potential of ATP6V1H: A V-ATPase H Subunit as a Drug Target and Biomarker

Introduction

ATP (adenosine triphosphate) is a crucial molecule in the cell's energy metabolism. It is the energy carrier of the cell, playing a vital role in powering various cellular processes, including muscle contractions, neural transmission, and chromatin remodeling. The V-ATPase ( V-ATPase H subunit) is an essential protein that enables ATP production and degradation in the cells. In this article, we will explore the potential of ATP6V1H as a drug target and biomarker.

1. Background

ATP is generated from the adenosine breakdown, which requires the assistance of the V-ATPase. The V-ATPase is a transmembrane protein that consists of two subunits: the V-ATPase H subunit and the V-ATPase C subunit. The H subunit is responsible for generating ATP by phosphorylating the ADP (adenosine diphosphate) at its active site. The V-ATPase H subunit is a 21-kDa protein that contains 10 known essential amino acids, including a highly conserved cal hydrophobic amino acid, D- Glu-215.

2. ATP6V1H as a Drug Target

The V-ATPase H subunit plays a crucial role in the regulation of ATP homeostasis. It is known to be involved in various cellular processes, including the regulation of ion channels, protein-protein interactions, and signaling pathways. Therefore, targeting the V- ATPase H subunit provides a promising strategy for developing new drugs with various therapeutic effects.

One of the promising targets for the V-ATPase H subunit is the inhibition of ATP-dependent processes, which may lead to therapeutic benefits. For instance, recent studies have shown that inhibitors of the V-ATPase H subunit can effectively inhibit the formation of ATP in response to various cellular stress conditions, such as thermal stress, radiation, and oxidative stress. These findings imply that targeting the V-ATPase H subunit may be an effective strategy for the development of anti-stress and anti-inflammatory drugs.

2. ATP6V1H as a Biomarker

The V-ATPase H subunit is a potential biomarker for various diseases due to its involvement in various cellular processes. The H subunit plays a critical role in the regulation of ATP homeostasis, which is closely associated with various diseases, including heart failure, diabetes, and neurodegenerative disorders.

One of the significant applications of the V-ATPase H subunit as a biomarker is its potential to predict the outcomes of various diseases. For instance, recent studies have shown that the H subunit of the V-ATPase can be predicted accurately using computational methods and biochemical assays. These findings imply that the V-ATPase H subunit may be a promising biomarker for various diseases and can be used to develop personalized therapies.

3. ATP6V1H Inhibition in Cancer

In cancer, the V-ATPase H subunit is often aberrantly expressed, which may contribute to the survival and proliferation of the cancer cells. Therefore, inhibiting the V-ATPase H subunit has been shown to be an effective strategy for the treatment of cancer.

Several studies have shown that inhibitors of the V-ATPase H subunit can effectively inhibit the growth and survival of various cancer cell lines, including breast, lung, and ovarian cancer. These findings imply that targeting the V-ATPase H subunit may be an effective strategy for the development of anti-cancer drugs.

4. Conclusion

In conclusion, the V-ATPase H subunit is a crucial protein that plays a vital role in the regulation of AT

Protein Name: ATPase H+ Transporting V1 Subunit H

Functions: Subunit of the V1 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (PubMed:33065002). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (By similarity). Subunit H is essential for V-ATPase activity, but not for the assembly of the complex (By similarity). Involved in the endocytosis mediated by clathrin-coated pits, required for the formation of endosomes (PubMed:12032142)

The "ATP6V1H Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP6V1H comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ATP7A | ATP7B | ATP8 | ATP8A1 | ATP8A2 | ATP8B1 | ATP8B1-AS1 | ATP8B2 | ATP8B3 | ATP8B4 | ATP8B5P | ATP9A | ATP9B | ATPAF1 | ATPAF2 | ATPase | ATPSCKMT | ATR | ATRAID | Atrial natriuretic peptide (ANP) receptor | ATRIP | ATRN | ATRNL1 | ATRX | ATXN1 | ATXN10 | ATXN1L | ATXN2 | ATXN2L | ATXN3 | ATXN3L | ATXN7 | ATXN7L1 | ATXN7L2 | ATXN7L3 | ATXN7L3B | ATXN8OS | Augmin | AUH | AUNIP | AUP1 | AURKA | AURKAIP1 | AURKAP1 | AURKB | AURKC | Aurora Kinase | AUTS2 | AVEN | AVIL | AVL9 | AVP | AVPI1 | AVPR1A | AVPR1B | AVPR2 | AWAT1 | AWAT2 | AXDND1 | AXIN1 | AXIN2 | AXL | Axonemal dynein complex | AZGP1 | AZGP1P1 | AZGP1P2 | AZI2 | AZIN1 | AZIN2 | AZU1 | B-cell Antigen Receptor Complex | B2M | B3GALNT1 | B3GALNT2 | B3GALT1 | B3GALT1-AS1 | B3GALT2 | B3GALT4 | B3GALT5 | B3GALT5-AS1 | B3GALT6 | B3GALT9 | B3GAT1 | B3GAT1-DT | B3GAT2 | B3GAT3 | B3GLCT | B3GNT2 | B3GNT3 | B3GNT4 | B3GNT5 | B3GNT6 | B3GNT7 | B3GNT8 | B3GNT9 | B3GNTL1 | B4GALNT1 | B4GALNT2 | B4GALNT3 | B4GALNT4